Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | April 01, 2022 | April 05, 2022 |
| ELI LILLY & CoLLY · Entity 2794 | EVP, Science and Technology | December 31, 2009 | February 03, 2010 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
| Sage Therapeutics, Inc.SAGE · Entity 77038 | Director | January 03, 2024 | January 04, 2024 |
| Seaport Therapeutics, Inc.SPTX · Entity 4799 | Director | April 30, 2026 | May 04, 2026 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director | June 03, 2021 | June 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date April 01, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000 |
Ending reported balance
After 2022-04-01 transaction · row 11
11 source rows · reconciled sequenceRow 1 · 2022-04-01 · Exercise / conversion · Acquired 15,000 · Balance 16,000 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Row 2 · 2022-04-01 · Sale · Disposed 253 · Balance 15,747 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F2: Sale prices ranged from $165.91 to $166.41. Row 3 · 2022-04-01 · Sale · Disposed 4,948 · Balance 10,799 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F3: Sale prices ranged from $168.30 to $169.30. Row 4 · 2022-04-01 · Sale · Disposed 4,872 · Balance 5,927 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F4: Sale prices ranged from $169.32 to $170.28. Row 5 · 2022-04-01 · Sale · Disposed 1,235 · Balance 4,692 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F5: Sale prices ranged from $170.70 to $171.63. Row 6 · 2022-04-01 · Sale · Disposed 1,434 · Balance 3,258 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F6: Sale prices ranged from $171.75 to $172.73. Row 7 · 2022-04-01 · Sale · Disposed 642 · Balance 2,616 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F7: Sale prices ranged from $172.83 to $173.37. Row 8 · 2022-04-01 · Sale · Disposed 90 · Balance 2,526 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Row 9 · 2022-04-01 · Sale · Disposed 526 · Balance 2,000 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F8: Sale prices ranged from $176.04 to $176.88. Row 10 · 2022-04-01 · Sale · Disposed 825 · Balance 1,175 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F9: Sale prices ranged from $177.12 to $178.00. Row 11 · 2022-04-01 · Sale · Disposed 175 · Balance 1,000 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.33 · Expires 2022-06-21 | Direct | 0 |
Reported balance
After 2022-04-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-04-01 · Exercise / conversion · Disposed 15,000 · Balance 0 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022.
F2: Sale prices ranged from $165.91 to $166.41.
F3: Sale prices ranged from $168.30 to $169.30.
F4: Sale prices ranged from $169.32 to $170.28.
F5: Sale prices ranged from $170.70 to $171.63.
F6: Sale prices ranged from $171.75 to $172.73.
F7: Sale prices ranged from $172.83 to $173.37.
F8: Sale prices ranged from $176.04 to $176.88.
F9: Sale prices ranged from $177.12 to $178.00.
ELI LILLY & Co
Report date December 31, 2009 · Filed February 03, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,000 |
Ending reported balance
After 2009-12-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2009-12-22 · Gift · Disposed 8,553 · Balance 33,854 Row 2 · 2009-12-23 · Gift · Disposed 28,854 · Balance 5,000 |
| Common StockSEC Table I · non-derivative | Indirectby wife | 37,407 |
Last balance in matching sequence
After 2009-12-23 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 3 · 2009-12-22 · Gift · Acquired 8,553 · Balance 8,553 F1: Reporting person disclaims beneficial ownership of these shares. Row 4 · 2009-12-23 · Gift · Acquired 28,854 · Balance 37,407 F1: Reporting person disclaims beneficial ownership of these shares. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 909 |
Reported balance
Holding disclosure · report date 2009-12-31 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 909 |
| Common StockSEC Table I · non-derivative | Indirectby daughter | 579 |
Reported balance
Holding disclosure · report date 2009-12-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 579 F1: Reporting person disclaims beneficial ownership of these shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting person disclaims beneficial ownership of these shares.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
Sage Therapeutics, Inc.
Report date January 03, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.67 · Expires 2034-01-03 | Direct | 3,971 |
Reported balance
After 2024-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-03 · Grant · Acquired 3,971 · Balance 3,971 F1: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2024 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2024, subject to the reporting person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2024 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2024, subject to the reporting person's continued service through such date.
Seaport Therapeutics, Inc.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 863,031 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Conversion · Acquired 67,031 · Balance 863,031 F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29 | Direct | 12,258 |
Reported balance
After 2026-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-30 · Grant · Acquired 12,258 · Balance 12,258 F2: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29 | Direct | 991,192 |
Reported balance
After 2026-04-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-30 · Grant · Acquired 991,192 · Balance 991,192 |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-04 · Conversion · Disposed 210,526 · Balance 0 F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
F2: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.
Voyager Therapeutics, Inc.
Report date June 03, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.23 · Expires 2031-06-03 | Direct | 15,000 |
Reported balance
After 2021-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-03 · Grant · Acquired 15,000 · Balance 15,000 F1: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Karuna Therapeutics, Inc.
Report date March 18, 2024 · Filed March 18, 2024
Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,550 |
Reported balance
After 2024-03-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-03-18 · Disposition to issuer · Disposed 2,046 · Balance 8,550 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-03-18 · Disposition to issuer · Disposed 8,550 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F4: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectSteve M. Paul Family 2021 Delaware Trust | 0 |
Reported balance
After 2024-03-18 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-03-18 · Disposition to issuer · Disposed 30,304 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. |
| Common StockSEC Table I · non-derivative | IndirectJann E Paul Revocable Trust | 0 |
Reported balance
After 2024-03-18 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2024-03-18 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. |
| Common StockSEC Table I · non-derivative | IndirectThe Steven M Paul Revocable Trust | 0 |
Reported balance
After 2024-03-18 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2024-03-18 · Disposition to issuer · Disposed 33,882 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13. |
| Common StockSEC Table I · non-derivative | IndirectSteven M. Paul Family 2024 Trust | 0 |
Reported balance
After 2024-03-18 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2024-03-18 · Disposition to issuer · Disposed 30,304 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. |
| Common StockSEC Table I · non-derivative | IndirectJann E. Paul GRAT III | 0 |
Reported balance
After 2024-03-18 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2024-03-18 · Disposition to issuer · Disposed 35,877 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.04 · Expires 2028-04-29 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-03-18 · Disposition to issuer · Disposed 136,094 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2028-08-08 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-03-18 · Disposition to issuer · Disposed 757,045 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-03-20 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-03-18 · Disposition to issuer · Disposed 449,463 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-03-28 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-03-18 · Disposition to issuer · Disposed 87,494 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-04-07 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-03-18 · Disposition to issuer · Disposed 15,205 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2019-06-26 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2024-03-18 · Disposition to issuer · Disposed 616,703 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.02 · Expires 2019-06-27 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2024-03-18 · Disposition to issuer · Disposed 71,121 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.72 · Expires 2030-02-13 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2024-03-18 · Disposition to issuer · Disposed 135,992 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.64 · Expires 2031-02-22 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2024-03-18 · Disposition to issuer · Disposed 161,850 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F7: These Options vested as to 25% on February 23, 2022, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $111.97 · Expires 2032-02-16 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2024-03-18 · Disposition to issuer · Disposed 146,900 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F8: These Options vested as to 25% on February 16, 2023, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $187.26 · Expires 2023-02-08 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2024-03-18 · Disposition to issuer · Disposed 22,800 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F9: These Options vested as to 25% on February 9, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers.
F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F3: Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13.
F4: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.
F6: These Options are fully vested.
F7: These Options vested as to 25% on February 23, 2022, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.
F8: These Options vested as to 25% on February 16, 2023, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.
F9: These Options vested as to 25% on February 9, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2006 Filed Apr 25, 2006 19:51 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 25,000 | $52.80 | $1,320,000.00 |
DisclosureSEC source: 0001209191-06-025341 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,656 Read SEC document |
| February 10, 2006 Filed Feb 14, 2006 21:54 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantEmployee stock option 2/06 (right to buy) · Derivative | 72,289 | $0.00 Strike: $56.18 | $0.00 |
DisclosureSEC source: 0001209191-06-010463 · doc4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,289 Underlying: Common Stock · 72,289 shares Expires 2016-02-09 Read SEC document |
| February 02, 2006 Filed Feb 3, 2006 19:42 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 6,201 | $57.00 | $353,457.00 |
DisclosureSEC source: 0001209191-06-007632 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,656 Read SEC document |
| February 01, 2006 Filed Feb 3, 2006 13:09 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 2,799 | $56.62 | $158,479.38 |
DisclosureSEC source: 0001209191-06-007504 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,857 Read SEC document |
| January 20, 2006 Filed Jan 24, 2006 20:50 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 21,564 | $57.04 | $1,230,010.56 |
DisclosureSEC source: 0001209191-06-004730 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,656 Read SEC document |
| December 23, 2005 Filed Feb 14, 2006 21:26 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 2,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-06-010418 · doc5.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 4,836 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 23, 2005 Filed Feb 14, 2006 21:26 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 2,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-06-010418 · doc5.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,092 Read SEC document |
| December 15, 2005 Filed Dec 19, 2005 22:00 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 10/96 (right to buy) · Derivative | 13,110 | $0.00 Strike: $34.60 | $0.00 |
DisclosureSEC source: 0001209191-05-064228 · doc4.xml · derivative · entry 7 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,890 Underlying: Common Stock · 13,110 shares Expires 2006-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2005 Filed Dec 19, 2005 22:00 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 10,150 | $55.96 | $567,994.00 |
DisclosureSEC source: 0001209191-05-064228 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,052 Read SEC document |
| December 15, 2005 Filed Dec 19, 2005 22:00 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 13,110 | $34.59 | $453,474.90 |
DisclosureSEC source: 0001209191-05-064228 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2005 Filed Oct 17, 2005 21:54 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 10/95 (right to buy) · Derivative | 19,728 | $0.00 Strike: $23.41 | $0.00 |
DisclosureSEC source: 0001209191-05-052594 · doc4.xml · derivative · entry 12 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,728 shares Expires 2005-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2005 Filed Oct 17, 2005 21:54 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 48,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-05-052594 · doc4.xml · nonDerivative · entry 7 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 2,049 F2 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| October 14, 2005 Filed Oct 17, 2005 21:54 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 48,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-05-052594 · doc4.xml · nonDerivative · entry 6 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,919 Read SEC document |
| October 14, 2005 Filed Oct 17, 2005 21:54 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 12,165 | $52.54 | $639,149.10 |
DisclosureSEC source: 0001209191-05-052594 · doc4.xml · nonDerivative · entry 5 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,662 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2005. Read SEC document |
| October 14, 2005 Filed Oct 17, 2005 21:54 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 19,728 | $23.41 | $461,783.16 |
DisclosureSEC source: 0001209191-05-052594 · doc4.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2005. Read SEC document |
| October 13, 2005 Filed Oct 17, 2005 21:54 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 10/95 (right to buy) · Derivative | 4,272 | $0.00 Strike: $23.41 | $0.00 |
DisclosureSEC source: 0001209191-05-052594 · doc4.xml · derivative · entry 11 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,728 Underlying: Common Stock · 4,272 shares Expires 2005-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2005 Filed Oct 17, 2005 21:54 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 4,272 | $23.41 | $99,996.84 |
DisclosureSEC source: 0001209191-05-052594 · doc4.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2005. Read SEC document |
| July 28, 2005 Filed Oct 17, 2005 21:54 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 87 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-05-052594 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,827 Read SEC document |
| May 26, 2005 Filed Oct 17, 2005 21:54 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 86 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-05-052594 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,914 Read SEC document |
| February 11, 2005 Filed Feb 15, 2005 22:12 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantEmployee stock option (right to buy) · Derivative | 85,207 | $0.00 Strike: $55.65 | $0.00 |
DisclosureSEC source: 0000059478-05-000066 · doc4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,207 Underlying: Common Stock · 85,207 shares Expires 2015-02-10 Read SEC document |
| January 14, 2005 Filed Jan 18, 2005 19:40 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 9,000 | $56.79 | $511,110.00 |
DisclosureSEC source: 0000059478-05-000015 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,818 Read SEC document |
| December 28, 2004 Filed Feb 14, 2005 23:51 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 234 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-05-000050 · doc5.xml · nonDerivative · entry 9 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 50,306 F1 · balance_after: Beginning with Dr. Paul's Form 3, dated July 1, 2003, 10,504 shares belonging to his wife have been erroneously reported as direc tly owned. The totals have been adjusted in this filing. F2 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| September 27, 2004 Filed Sep 29, 2004 19:12 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 18,700 | $0.00 Strike: $14.66 | $0.00 |
DisclosureSEC source: 0000059478-04-000149 · doc4.xml · derivative · entry 7 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,700 shares Expires 2004-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2004 Filed Sep 29, 2004 19:12 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 8,386 | $63.66 | $533,852.76 |
DisclosureSEC source: 0000059478-04-000149 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,818 Read SEC document |
| September 27, 2004 Filed Sep 29, 2004 19:12 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 18,700 | $14.66 | $274,095.25 |
DisclosureSEC source: 0000059478-04-000149 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2004 Filed Feb 14, 2005 23:51 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 10,314 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-05-000050 · doc5.xml · nonDerivative · entry 8 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 50,540 F3 · ownership.direct: Represents transfer of shares to wife Read SEC document |
| September 27, 2004 Filed Feb 14, 2005 23:51 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 10,314 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-05-000050 · doc5.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 F1 · balance_after: Beginning with Dr. Paul's Form 3, dated July 1, 2003, 10,504 shares belonging to his wife have been erroneously reported as direc tly owned. The totals have been adjusted in this filing. Read SEC document |
| June 02, 2004 Filed Feb 14, 2005 23:51 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 1,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-05-000050 · doc5.xml · nonDerivative · entry 7 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 40,226 F3 · ownership.direct: Represents transfer of shares to wife Read SEC document |
| June 02, 2004 Filed Feb 14, 2005 23:51 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 617 | $74.74 | $46,114.58 |
DisclosureSEC source: 0000059478-05-000050 · doc5.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,314 Read SEC document |
| June 02, 2004 Filed Feb 14, 2005 23:51 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 1,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-05-000050 · doc5.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,931 Read SEC document |
| April 13, 2004 Filed Feb 14, 2005 23:51 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 109 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-05-000050 · doc5.xml · nonDerivative · entry 6 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 38,843 F2 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| February 17, 2004 Filed Feb 19, 2004 20:03 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantEmployee stock option (right to buy) · Derivative | 120,000 | $0.00 Strike: $73.11 | $0.00 |
DisclosureSEC source: 0000059478-04-000076 · doc4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2014-02-14 Read SEC document |
| December 17, 2003 Filed Feb 17, 2004 19:29 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 213 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-04-000032 · doc5.xml · nonDerivative · entry 5 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 28,448 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 16, 2003 Filed Feb 17, 2004 19:29 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 216 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-04-000032 · doc5.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 28,661 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| August 05, 2003 Filed Aug 5, 2003 19:45 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 10,000 | $64.87 | $648,716.00 |
DisclosureSEC source: 0000059478-03-000022 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 28,877 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| Date not disclosed Filed Jul 10, 2003 20:05 UTC | ELI LILLY & Co LLY · Entity 2794 | OtherCommon Stock | 589 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000059478-03-000012 · doc3.xml · nonDerivative · entry 5 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife as custodian for son Disclosed balance after: Not disclosed F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| Date not disclosed Filed Jul 10, 2003 20:05 UTC | ELI LILLY & Co LLY · Entity 2794 | OtherCommon Stock | 38,877 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000059478-03-000012 · doc3.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: Not disclosed F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| Date not disclosed Filed Jul 10, 2003 20:05 UTC | ELI LILLY & Co LLY · Entity 2794 | OtherCommon Stock | 579 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000059478-03-000012 · doc3.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by daughter Disclosed balance after: Not disclosed F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| Date not disclosed Filed Jul 10, 2003 20:05 UTC | ELI LILLY & Co LLY · Entity 2794 | OtherCommon Stock | 2,105 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000059478-03-000012 · doc3.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Disclosed balance after: Not disclosed Read SEC document |
| Date not disclosed Filed Jul 10, 2003 20:05 UTC | ELI LILLY & Co LLY · Entity 2794 | OtherCommon Stock | 20,504 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000059478-03-000012 · doc3.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.